MOLNSEMeghmani Organics LimitedMediumNeutral
Announced Sat, 4 Apr · 14:18 IST

Meghmani Organics Limited has informed the Exchange regarding Outcome of Board Meeting held on April 04, 2026 approving the scheme of amalgamation of Kilburn Chemicals Limited and Meghmani Crop Nutrition Limited being wholly owned subsidiaries with Meghmani Organics Limited.

Strategic Transactions View source PDF

MOL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+6.0%1-day move
₹44.71
prior close
₹44.94
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.7-0.7-1.6-1.0+6.0+10.7+8.2+11.4+8.5+18.8+17.0+31.0+5.8+5.8
Up moveDown movePending
AI summary

The Board of Meghmani Organics Limited (MOL), held on April 4, 2026, approved a Scheme of Amalgamation to merge its two wholly owned subsidiaries—Kilburn Chemicals Limited (engaged in Titanium Dioxide manufacturing) and Meghmani Crop Nutrition Limited (engaged in crop nutrition)—into itself. The appointed date is January 1, 2026. Since both are wholly owned subsidiaries, no share exchange ratio applies and MOL's shareholding pattern will remain unchanged (Promoters 48.98%, Public 51.02%). Kilburn Chemicals has total assets of about ₹657 crore and turnover of ₹49.76 crore; Meghmani Crop Nutrition has assets of about ₹116 crore and turnover of ₹25.23 crore, compared to MOL's standalone assets of about ₹3,095 crore and turnover of ₹1,635 crore. The scheme requires NCLT, shareholder, creditor, and regulatory approvals before becoming effective. The rationale cited includes simplification of group structure, operational and financial synergies, cost reduction, and elimination of duplication.

Likely market impact

This is an internal group restructuring with no change in shareholding or dilution for existing shareholders. It should streamline operations and reduce duplication, but is unlikely to have a material near-term impact on the stock price. Investors should monitor NCLT and shareholder approval timelines for confirmation.